Table 1.
Characteristics of rheumatoid arthritis patients.
| Patients | Age range (years) | Current treatments | Disease duration (months) | DAS28 | Anti-CCP | Erosion | RF |
|---|---|---|---|---|---|---|---|
| PAT-1 | 36–40 | Prednisone | 28 | 2.70 | Yes | Yes | Yes |
| PAT-2 | 80–85 | Tocilizumab | 172 | 6.85 | Yes | Yes | Yes |
| PAT-3 | 40–45 | Nonsteroidal anti-inflammatory drugs | 124 | 5.49 | Yes | Yes | Yes |
| PAT-4 | 71–75 | Tocilizumab | 76 | 3.49 | Yes | Yes | No |
| PAT-5 | 81–85 | Etanercept, Methotrexate | 136 | 2.68 | Yes | Yes | NA |
| PAT-6 | 56–60 | Methotrexate | 76 | 1.89 | NA | NA | NA |
| PAT-7 | 56–60 | Methotrexate Hydroxychloroquine, Salazopyrine, Prednisone | 148 | 2.58 | Yes | No | Yes |
| PAT-8 | 50–55 | Rituximab, Methotrexate | 244 | 2.97 | Yes | Yes | Yes |
| PAT-9 | 56–70 | Rituximab, Methotrexate | 304 | 2.56 | Yes | Yes | Yes |
The age range, and previous and current treatments, as well as the presence of anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), and/or joints erosion indicated for each RA-treated patient. Characteristics of patients correspond to information collected at the time of blood sampling.